Credit Suisse Downgrades Kymera Therapeutics (KYMR) to Neutral

(Updated - December 5, 2022 4:05 PM EST)

Credit Suisse analyst Richard Law downgraded Kymera Therapeutics (NASDAQ: KYMR) from Outperform to Neutral with a price target of $32.00 (from $47.00).

The analyst comments "Based on our assessment, we have reduced POS for KT-474 in AD from 20% to 13% (HS still at 10%), and reduced M&A weight to 10% (from 15%). As a result, our TP decreases to $32 (from $47), and our rating is now Neutral (from Outperform). Risks include worse/better clinical outcomes than expected."

For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.

Shares of Kymera Therapeutics closed at $30.78 yesterday.

You May Also Be Interested In

• Guggenheim remains bullish on WWE’s renewal cycle
• Mapletree Commercial Trust (MACT:SP) (MPCMF) PT Raised to SGD1.95 at JPMorgan
• Wells Fargo cuts SLM Corp. (SLM) as credit issues persist